Microribonucleic acids as potential markers in cardiovascular diseases

Cardiovascular diseases (CVDs) are one of the most common causes of death in the developed as well as in the developing world. Despite improvements in primary prevention, the prevalence of CVD has continued to rise in recent years. Thus, the issues of molecular pathophysiology of CVD and search for new biomarkers related to early and reliable prevention and diagnosis of these diseases still hold relevance today. New genomic techniques provide innovative tools to solve this problem. A research of the current scientific literature clearly indicates that among transcriptomic biomarkers, micro-ribonucleic acids (miRNAs) are the most promising. The microRNAs (miRNAs) are small (~22 nucleotides) non-coding RNAs which regulate gene expression at the post-transcriptional level via inhibition of the translation of messenger RNA (mRNA) or by inducing the degradation of specific miRNAs. The lack of consensus regarding methodologies used for miRNA quantification is one of the main limiting factors in the application of these transcripts. Various studies have proposed the use of circulating miRNAs as biological markers of the acute coronary syndrome, coronary artery disease, heart failure, arrhythmias, myocardial infarction, etc. MiRNAs are involved in many cellular processes such as proliferation, vasculogenesis, apoptosis, cell growth and differentiation, and tumorigenesis.
This review considers the most fully studied and clinically significant miRNAs, which physiological role makes them potential biomarkers for various CVDs.

1. Kim SJ, Mesquita FCP, Hochman-Mendez C. New Biomarkers for Cardiovascular Disease. Tex Heart Inst J. 2023;50(5):e238178. https://doi.org/10.14503/THIJ-23-8178.

2. Çakmak HA, Demir M. MicroRNA and Cardiovascular Diseases. Balkan Med J. 2020;37(2):60–71. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.1.94.

3. Kamyshova ES, Bobkova IN, Kutyrina IM. New insights on microRNAs in diabetic nephropathy: potential biomarkers for diagnosis and therapeutic targets. Diabetes Mellitus. 2017;20(1):42–50. (In Russ.) https://doi.org/10.14341/DM8237.

4. Velikiy DA, Gichkun OE, Shevchenko AO. MicroRNAs: a role in the development of cardiovascular disease, the possibility for clinical application. Klinichescheskaya Laboratornaya Diagnostika. 2018;63(7):403–409. (In Russ.) Available at: https://clinlabdia.ru/article/mikrornk-rol-v-razvitii-serdechno-sos.

5. Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs’ Action through miRNA Editing. Int J Mol Sci. 2019;20(24):6249. https://doi.org/10.3390/ijms20246249.

6. de Gonzalo-Calvo D, Benítez ID, Pinilla L, Carratalá A, Moncusí-Moix A, Gort-Paniello C et al. Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Transl Res. 2021;236:147–159. https://doi.org/10.1016/j.trsl.2021.05.004.

7. Koroleva IA, Nazarenko MS, Kucher AN. Role of microRNA in Development of Instability of Atherosclerotic Plaques. Biochemistry (Moscow). 2018;83(1):34–46. (In Russ.) Available at: http://www.medgenetics.ru/UserFile/File/Doc/Publications/2018/2018-BioChim-Korol-microRNA.pdf.

8. Kucher AN, Nazarenko MS. The Role of MicroRNA in Atherogenesis. Kardiologiya. 2018;57(9):65–76. (In Russ.) https://doi.org/10.18087/cardio.2017.9.10022.

9. Romakina VV, Zhirov IV, Nasonova SN, Zaseeva AV, Kochetov AG, Liang OV, Tereshchenko SN. MicroRNAs as Biomarkers of Cardiovascular Diseases. Kardiologia. 2018;(1):66–71. (In Russ.) https://doi.org/10.18087/cardio.2018.1.10083.

10. Beresneva ON, Zaraiski MI, Kulikov AN, Parastaeva MM, Ivanova GT, Okovityi SV et al. MicroRNA-21 and myocardial remodeling with the reduction of the nephron mass. Arterial Hypertension (Russian Federation). 2019;25(2):191–199. (In Russ.) https://doi.org/10.18705/1607-419X-2019-25-2-191-199.

11. Mishra S, Rizvi A, Pradhan A, Perrone MA, Ali W. Circulating microRNA-126 &122 in patients with coronary artery disease: Correlation with small dense LDL. Prostaglandins Other Lipid Mediat. 2021;153:106536. https://doi.org/10.1016/j.prostaglandins.2021.106536.

12. Liu MN, Luo G, Gao WJ, Yang SJ, Zhou H. miR-29 family: A potential therapeutic target for cardiovascular disease. Pharmacol Res. 2021;166:105510. https://doi.org/10.1016/j.phrs.2021.105510.

13. Kura B, Kalocayova B, Devaux Y, Bartekova M. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int J Mol Sci. 2020;21(3):700. https://doi.org/10.3390/ijms21030700.

14. Song Z, Gao R, Yan B. Potential roles of microRNA-1 and microRNA-133 in cardiovascular disease. Rev Cardiovasc Med. 2020;21(1):57. https://doi.org/10.31083/j.rcm.2020.01.577.

15. Fung EC, Butt AN, Eastwood J, Swaminathan R, Sodi R. Circulating microRNA in cardiovascular disease. Advances in Clinical Chemistry. 2019;91:99–122. https://doi.org/10.1016/bs.acc.2019.03.003.

16. Gallant-Behm CL, Piper J, Lynch JM, Seto AG, Hong SJ, Mustoe TA et al. A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019;139(5):1073–1081. https://doi.org/10.1016/j.jid.2018.11.007.

17. Deng Z, He Y, Yang X, Shi H, Shi A, Lu L, He L. MicroRNA-29: A Crucial Player in Fibrotic Disease. Mol Diagn Ther. 2017;21(3):285–294. https://doi.org/10.1007/s40291-016-0253-9.

18. Li C, Wang N, Rao P, Wang L, Lu D, Sun L. Role of the microRNA-29 family in myocardial fibrosis. J Physiol Biochem. 2021;77(3):365–376. https://doi.org/10.1007/s13105-021-00814-z.

19. Liu Y, Song JW, Lin JY, Miao R, Zhong JC. Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases. Cardiovasc Toxicol. 2020;20(5):463–473. https://doi.org/10.1007/s12012-020-09603-4.

20. Sun X, Zhang M, Sanagawa A, Mori C, Ito S, Iwaki S et al. Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb J. 2012;10(1):16. https://doi.org/10.1186/1477-9560-10-16.

21. Zhang J, Guo J, Wu X, Wang X, Zhu Z, Wang Y et al. TWIST1 induces phenotypic switching of vascular smooth muscle cells by downregulating p68 and microRNA-143/145. FEBS Open Bio. 2021;11(3):932–943. https://doi.org/10.1002/2211-5463.13092.

22. Zhao W, Zhao SP, Zhao YH. MicroRNA-143/-145 in Cardiovascular Diseases. Biomed Res Int. 2015;2015:531740. https://doi.org/10.1155/2015/531740.

23. Wang X, Dong Y, Fang T, Wang X, Chen L, Zheng C et al. Circulating MicroRNA-423-3p Improves the Prediction of Coronary Artery Disease in a General Population – Six-Year Follow-up Results From the ChinaCardiovascular Disease Study. Circ J. 2020;84(7):1155–1162. https://doi.org/10.1253/circj.CJ-19-1181.

24. Xia X, Wang Y, Zheng JC. The microRNA-17 ~ 92 Family as a Key Regulator of Neurogenesis and Potential Regenerative Therapeutics of Neurological Disorders. Stem Cell Rev Rep. 2022;18(2):401–411. https://doi.org/10.1007/s12015-020-10050-5.

25. Danielson LS, Park DS, Rotllan N, Chamorro-Jorganes A, Guijarro MV, Fernandez-Hernando C et al. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J. 2013;27(4):1460–1467. https://doi.org/10.1096/fj.12-221994.

26. Gu H, Liu Z, Zhou L. Roles of miR-17-92 Cluster in Cardiovascular Development and Common Diseases. Biomed Res Int. 2017;2017:9102909. https://doi.org/10.1155/2017/9102909.

27. Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail. 2010;16(5):404–410. https://doi.org/10.1016/j.cardfail.2010.01.002.

28. Han Z, Zhang L, Yuan L, Liu X, Chen X, Ye X et al. Change of plasma microRNA-208 level in acute myocardial infarction patients and its clinical significance. Ann Transl Med. 2015;3(20):307. https://doi.org/10.3978/j.issn.2305-5839.2015.10.25.

29. Zhao X, Wang Y, Sun X. The functions of microRNA-208 in the heart. Diabetes Res Clin Pract. 2020;160:108004. https://doi.org/10.1016/j.diabres.2020.108004.

30. Wang J, Xu L, Tian L, Sun Q. Circulating microRNA-208 family as early diagnostic biomarkers for acute myocardial infarction: A meta-analysis. Medicine (Baltimore). 2021;100(51):e27779. https://doi.org/10.1097/MD.0000000000027779.

31. Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A et al. Cardiac Troponin T and Troponin I in the General Population. Circulation. 2019;139(24):2754–2764. https://doi.org/10.1161/CIRCULATIONAHA.118.038529.

32. Huang Y, Li J. MicroRNA208 family in cardiovascular diseases: therapeutic implication and potential biomarker. J Physiol Biochem. 2015;71(3):479–486. https://doi.org/10.1007/s13105-015-0409-9.

33. Bao MH, Feng X, Zhang YW, Lou XY, Cheng Y, Zhou HH. Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells. Int J Mol Sci. 2013;14(11):23086–23102. https://doi.org/10.3390/ijms141123086.

34. Krzywińska O, Bracha M, Jeanniere C, Recchia E, Kędziora Kornatowska K, Kozakiewicz M. Meta-Analysis of the Potential Role of miRNA-21 in Cardiovascular System Function Monitoring. Biomed Res Int. 2020;2020:4525410. https://doi.org/10.1155/2020/4525410.

35. Alieva AM, Reznik EV, Teplova NV, Melikulov AA, Akhmedova MF, Kotikova IA, Nikitin IG. MicroRNA-34a in cardiovascular disease: a glimpse into the future. Russian Cardiology Bulletin. 2023;18(1):14–22. (In Russ.) https://doi.org/10.17116/Cardiobulletin20231801114.